Upregulation of miR-361-5p attenuates MPP+-induced neurotoxicity in dopaminergic SH-SY5Y cells as Parkinson's disease model
Journal of Biological Chemistry · 2025-12 · 301 (12) · 110912
DOI: 10.1016/j.jbc.2025.110912 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2025-12. Verfasst von Shiva Vaheb Hosseinabadi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, Faculty of Science, Razi University, Kermanshah, Iran. Hauptthemen laut MEDLINE: MicroRNAs, 1-Methyl-4-phenylpyridinium, Up-Regulation, Dopaminergic Neurons. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Programmed cell death plays a crucial role in the pathogenesis of Parkinson's disease, yet the involvement of microRNAs (miRNAs) in this process remains inadequately understood. Previous studies have indicated a decreased expression pattern of hsa-miR-361-5p in patients with neurodegenerative diseases and in cell models of these conditions. This study aimed to predict the target genes of hsa-miR-361-5p, and to validate the predicted interactions at the mRNA level between hsa-miR-361-5p and its predicted target genes. In addition, we investigated the potential neuroprotective effect of miR-361-5p by assessing its effects on apoptosis and cell viability in SHSY-5Y cells using MTS assay and flow cytometry. Notably, overexpression of miR-361-5p significantly attenuated MPP+-induced neurotoxicity. Utilizing bioinformatics and dual-luciferase reporter assays, heme oxygenase 1 (HMOX1) and Fas associated via death domain (FADD) were identified as direct targets of miR-361-5p. Moreover, overexpression of miR-361-5p led to a decrease in the expression of HMOX1 and FADD genes, both known to be involved in cell death processes such as apoptosis and ferroptosis. Our findings indicate that miR-361-5p regulates the expression of HMOX1 and FADD, suggesting that miR-361-5p may represent a potential therapeutic target in Parkinson's disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biology, Faculty of Science, Razi University, Kermanshah, Iran.
- Department of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
- Department of Biology, Faculty of Science, NourDanesh Institute of Higher Education, Isfahan, Iran.
- Department of Biology, Faculty of Science, Hakim Sabzevari University, Sabzevar, Iran.
- Department of Animal Biotechnology, Cell Science Research Center, Royan Institute for Biotechnology, ACECR, Isfahan, Iran.
- Department of Biology, ShK.C., Islamic Azad University, Shahrekord, Iran. Electronic address: m.peymani@iau.ac.ir.
Zitieren
APA
Vaheb Hosseinabadi, S., Tahamtan, H., Mahmoudian Esfahani, M., Ghaedi-Heidari, R., Hashemi, M. S., Peymani, M., Sisakhtnezhad, S., Fahimi, H., & Ghaedi, K. (2025). Upregulation of miR-361-5p attenuates MPP+-induced neurotoxicity in dopaminergic SH-SY5Y cells as Parkinson's disease model. Journal of Biological Chemistry, 301(12), 110912. https://doi.org/10.1016/j.jbc.2025.110912
Vancouver
Vaheb Hosseinabadi S, Tahamtan H, Mahmoudian Esfahani M, Ghaedi-Heidari R, Hashemi MS, Peymani M, et al. Upregulation of miR-361-5p attenuates MPP+-induced neurotoxicity in dopaminergic SH-SY5Y cells as Parkinson's disease model. Journal of Biological Chemistry. 2025;301(12):110912. doi:10.1016/j.jbc.2025.110912
BibTeX
@article{VahebHosseinabadi2025,
author = {Vaheb Hosseinabadi, Shiva and Tahamtan, Hananeh and Mahmoudian Esfahani, Maryam and Ghaedi-Heidari, Rasoul and Hashemi, Motahare-Sadat and Peymani, Maryam and Sisakhtnezhad, Sajjad and Fahimi, Hossein and Ghaedi, Kamran},
title = {Upregulation of miR-361-5p attenuates MPP+-induced neurotoxicity in dopaminergic SH-SY5Y cells as Parkinson's disease model},
journal = {Journal of Biological Chemistry},
year = {2025},
volume = {301},
number = {12},
pages = {110912},
doi = {10.1016/j.jbc.2025.110912}
}
EUVIMED